TABLE III.
POCEs at 2-Year Follow-Up According to Bleeding Risk Score
| Risk group | All patients, No. (%)(N = 1080) | Any POCE, No. (%) (n = 230) | All-cause death, No. (%) (n = 72) | Myocardial infarction, No. (%) (n = 54) | Repeat revascularization, No. (%) (n = 150) |
|---|---|---|---|---|---|
| HAS-BLED score | |||||
| Low (0) | 0 (0) | 0 | 0 | 0 | 0 |
| Intermediate (1-2) | 675 (62.5) | 120 (17.8) | 23 (3.4) | 25 (3.7) | 92 (13.6) |
| High (≥3) | 405 (37.5) | 110 (27.2) | 49 (12.1) | 29 (7.2) | 58 (14.3) |
| P value | <.01 | <.01 | .01 | .79 | |
| HEMORR2HAGES score | |||||
| Low (0-1) | 475 (44) | 84 (17.7) | 14 (3) | 16 (3.4) | 67 (14.1) |
| Intermediate (2-3) | 521 (48.2) | 118 (22.6) | 40 (7.7) | 33 (6.3) | 71 (13.6) |
| High (≥4) | 84 (7.8) | 28 (33.3) | 18 (21.4) | 5 (6.0) | 12 (14.3) |
| P value | <.01 | <.01 | .09 | .97 | |
| PARIS scorea | |||||
| Low (0-3) | 454 (42.0) | 81 (17.8) | 11 (2.4) | 17 (3.7) | 66 (14.5) |
| Intermediate (4-7) | 483 (44.7) | 105 (21.7) | 28 (5.8) | 26 (5.4) | 72 (14.9) |
| High (≥8) | 143 (13.2) | 44 (30.8) | 33 (23.1) | 11 (7.7) | 12 (8.4) |
| P value | <.01 | <.01 | .15 | .12 | |
HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol; HEMORR2HAGES, Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall Risk and Stroke; PARIS, Patterns of non-Adherence to Anti-Platelet Regimen in Stented Patients; POCE, patient-oriented composite end point.
P < .05 was considered statistically significant.
a
Percentages of all patients’ PARIS scores may not total 100.0% due to rounding.